| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_08cbd1d8798da9ca90a726487c488ef1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_da837bfca483efea04a82b0af35f8848
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6b7842a4e9018c1adc74967d2d59c9be
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cdda2fe24381d2b66b710b5f080485fa |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-162
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 |
| filingDate |
2011-10-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_51e4a92b55c196d9ae32b9b9333200af
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1333697d318f39baa7c41043c81a908e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe7211047e2b371a7b51e63cdde868a4 |
| publicationDate |
2013-03-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2013072442-A1 |
| titleOfInvention |
Viral Complement Control Proteins for Eye Disorders |
| abstract |
The present invention provides compositions and methods for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the compositions comprise a poxvirus complement control protein or a complement binding fragment or variant thereof. Other compositions comprise a poxvirus complement control protein linked to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the methods comprise administering a poxvirus complement control protein or complement binding fragment or variant thereof to a subject. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11040107-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11407789-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10407466-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10308687-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10941184-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10875893-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11292815-B2 |
| priorityDate |
2004-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |